Gemcitabine Delivery and Photodynamic Therapy in Cancer Cells via Porphyrin-Ethylene-Based Periodic Mesoporous Organosilica Nanoparticles

Dina Aggad, Chiara Mauriello Jimenez, Soraya Dib, Jonas G. Croissant, Laure Lichon, Danielle Laurencin, Sebastien Richeter, Marie Maynadier, Shahad K. Alsaiari, Makhlouf Boufatit, Laurence Raehm, Marcel Garcia, Niveen M. Khashab, Magali Gary-Bobo*, Jean-Olivier Durand

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Gemcitabine hydrochloride is an FDA-approved chemotherapeutic drug used in the treatment of various cancers. Several drawbacks of gemcitabine, including its short in vivo half-life of 8-17min associated with a rapid excretion by the kidneys and its poor membrane permeability, have inspired research on a nanodelivery approach. In this study, we report ethylene-based periodic mesoporous organosilica nanoparticles (PMOs) for photodynamic therapy and the autonomous delivery of gemcitabine in cancer cells. Porphyrins were used as photosensitizers and were localized in the walls of the PMOs while a high loading capacity of gemcitabine was observed in the porous structure. Depending on the nature of the photosensitizer, and its aggregation state, we were able to perform one or two-photon photodynamic therapy. Two-photon excited photodynamic therapy combined with gemcitabine delivery led to a synergy and a very efficient cancer cell killing.

Original languageEnglish
Pages (from-to)46-51
Number of pages6
JournalChemNanoMat
Volume4
Issue number1
DOIs
StatePublished - Jan 2018

Keywords

  • gemcitabine
  • mesoporous organosilica nanoparticles
  • photodynamic therapy
  • porphyrin
  • two-photon
  • HUMAN PANCREATIC-CANCER
  • SILICA NANOPARTICLES
  • DRUG-DELIVERY
  • IN-VITRO
  • NANORODS
  • NANOSPHERES
  • ENHANCEMENT
  • RESISTANCE
  • CHEMISTRY
  • EMISSION

Cite this